Market News

Pfizer, Autodesk, and AbbVie in Focus Investment Insights: Pfizer, Autodesk, and AbbVie in Focus

On CNBC’s “Halftime Report Final Trades,” Liz Young of BNY Mellon Investment Management named Health Care Select Sector SPDR Fund XLV as her final trade.

Joshua Brown of Ritholtz Wealth Management picked Pfizer Inc. PFE, which bottomed in the middle of December.

At the JPMorgan Healthcare Conference, Pfizer CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning obesity market, despite setbacks involving a terminated weight-loss drug candidate due to severe side effects.

Karen Firestone of Aureus Asset Management picked Autodesk, Inc. ADSK.

Keybanc analyst Jason Celino, last week, maintained Autodesk with an Overweight and raised the price target from $245 to $260.

Bill Baruch of Blue Line Futures named AbbVie Inc. ABBV as his final trade.

Enigma Biomedical Group – USA signed an exclusive license and option agreement with AbbVie for the development and potential commercialization of AbbVie’s Novel 4R Tau PET Imaging Biomarkers. AbbVie is expected to announce its full-year and fourth-quarter 2023 financial results on Feb. 2, 2024, before the opening bell.

Analysts expect the company to report quarterly earnings at $2.9 per share on revenue of $13.99 billion.

Market Performance

  • Health Care Select Sector SPDR Fund slipped 0.01%.
  • Pfizer shares fell 0.2% to close at $28.09 on Thursday.
  • Autodesk gained 1.1% to $241.18.
  • AbbVie gained by 0.8% to $163.30 during Thursday’s session.

See also  Stock Market Update: Dow Surges Over 100 Points as Eli Lilly Reports Strong Earnings Stock Market Update: Dow Surges Over 100 Points as Eli Lilly Reports Strong Earnings